Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
14 angezeigte Treffer · Seite 1, keine Gesamtzahl für „leriglitazone“
Suchtreffer
Begriffe & Kennungen
Nezglyal · 4.5 · 6 Effect of leriglitazone on other medicinal products
Eintrag öffnenNezglyal · 4.5 · CYP2C8 and CYP3A inducers Concomitant use of leriglitazone with CYP2C8 and/or CYP3A inducers (e.g. carbamazepi
Eintrag öffnenNezglyal · 4.5 · CYP2C8 and CYP3A inhibitors Concomitant use of leriglitazone with strong and moderate CYP2C8 inhibitors (e.g.
Eintrag öffnenNezglyal · 4.5 · Interactions affecting leriglitazone
Eintrag öffnenNezglyal · 4.5 · Leriglitazone is predominantly metabolised by cytochrome P450 (CYP2C8 and CYP3A4) and it is a substrate of P-g
Eintrag öffnenNezglyal · 4.5 · Leriglitazone should not be used in patients receiving blood-glucose-lowering medicinal products. If concomita
Eintrag öffnenNezglyal · 4.5 · No clinical drug-drug interaction studies have been completed with leriglitazone to date.
Eintrag öffnenNezglyal · 4.5 · No drug–drug interaction studies with antidiabetic medicinal products have been completed with leriglitazone t
Eintrag öffnenNezglyal · 4.5 · Transporter interactions No effect is expected on the absorption of leriglitazone when given concomitantly wit
Eintrag öffnenNezglyal · 4.8 · In children (2 to 12 years of age), the most commonly reported adverse reactions during leriglitazone treatmen
Eintrag öffnenNezglyal · 4.8 · The overall safety profile of leriglitazone is based on clinical studies and additional clinical experience in
Eintrag öffnenNezglyal · 4.8 · The safety of leriglitazone in paediatric patients with ALD was evaluated in an open label Phase II study MT-2
Eintrag öffnenNezglyal · 4.8 · There are no data available on the use of leriglitazone in patients under 2 years of age.
Eintrag öffnenleriglitazone
Eintrag öffnen